Design of Personalized Neoantigen RNA Vaccines Against Cancer Based on Next-Generation Sequencing Data

Alburquerque-González, Begoña; López-Abellán, María Dolores; Luengo‐Gil, Ginés; Montoro-García, Silvia; Conesa‐Zamora, Pablo

doi:10.1007/978-1-0716-2573-6_7

Cited by 4 publications

(3 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it is a time for optimism in cancer immunotherapy, several exceptional questions remain unanswered. Although several predictive biomarkers have been widely investigated for immunotherapy response [156], currently only a few tumor-agnostic biomarkers are FDA-approved [157,158]. Furthermore, despite the many options available for immunotherapy, there is still no evidence to help us choose which of these deserves to be used in clinical trials over another.…”

Section: Discussionmentioning

confidence: 99%

Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy

Lauriola

Davalli

Marverti

et al. 2023

Cancers

View full text Add to dashboard Cite

Immunotherapy is a cancer treatment that exploits the capacity of the body’s immune system to prevent, control, and remove cancer. Immunotherapy has revolutionized cancer treatment and significantly improved patient outcomes for several tumor types. However, most patients have not benefited from such therapies yet. Within the field of cancer immunotherapy, an expansion of the combination strategy that targets independent cellular pathways that can work synergistically is predicted. Here, we review some consequences of tumor cell death and increased immune system engagement in the modulation of oxidative stress and ubiquitin ligase pathways. We also indicate combinations of cancer immunotherapies and immunomodulatory targets. Additionally, we discuss imaging techniques, which are crucial for monitoring tumor responses during treatment and the immunotherapy side effects. Finally, the major outstanding questions are also presented, and directions for future research are described.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy

Lauriola

Davalli

Marverti

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the identification of neoantigens in hepatocellular carcinoma (HCC) still presents a challenge. But with the emergence of next-generation sequencing technologies and advanced algorithms, the process of selecting neoantigens for personalized mRNA vaccines has become more attainable and feasible [ 51 ].…”

Section: Current Research Stage Of Applying Neoantigen Mrna Vaccine I...mentioning

confidence: 99%

Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment

Han,

Wang,

2023

Pharmaceutics

View full text Add to dashboard Cite

This study builds upon the groundbreaking mRNA vaccine Nobel Prize win in 2023 for COVID-19 prevention, paving the way for next-generation mRNA cancer vaccines to revolutionize immunotherapy. Despite the existing challenges, such as the presence of a suppressive tumor microenvironment and the identification of cancer-associated antigens, recent results from the KEYNOTE-942 trial have successfully demonstrated the effectiveness of mRNA-based cancer treatments, providing clinical evidence for the first time. This trial aimed to evaluate the efficacy and safety of combining immune checkpoint inhibitors with mRNA-based therapies in treating cancer. This advancement undeniably represents new hope for hepatocellular carcinoma (HCC) patients. However, progress in this field remains limited. In this article, we summarized the current state of applying immune checkpoint inhibitors (ICIs) combined with neoantigen mRNA vaccines. Additionally, we discussed potential targets for designing novel mRNA vaccines and potential mRNA vaccine delivery vehicles. The objective of this article is to inspire enthusiasm for the exploration of innovative therapeutic strategies that combine ICIs with neoantigen mRNA vaccines for HCC treatment and HCC prevention.

show abstract

“…Cancer vaccination is another clinical area that is considered a promising therapeutic strategy in treating solid tumors, and the wide accessibility of NGS has brought personalized cancer vaccines to the forefront of cancer research. Several studies have discussed the applications of NGS in the prediction of neoantigen targets for cancer vaccines and the design of personalized neoantigen RNA vaccines against cancer [ 8 , 9 ].…”

mentioning

confidence: 99%

Next-Generation Sequencing: A Promising Tool for Vaccines and Other Biological Products

Nellimarla

Kesanakurti

2023

Vaccines

View full text Add to dashboard Cite

show abstract

Design of Personalized Neoantigen RNA Vaccines Against Cancer Based on Next-Generation Sequencing Data

Cited by 4 publications

References 82 publications

Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy

Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy

Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment

Next-Generation Sequencing: A Promising Tool for Vaccines and Other Biological Products

Contact Info

Product

Resources

About